Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Royalty Pharma (RPRX) to $54 from $55 and keeps an Overweight rating on the shares. Ahead of Q3 earnings, the firm adjusted models for IQVIA trends as well as intra-quarter updates, the analyst tells investors in a preview for the biopharma group.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma: Strategic Positioning and Growth Potential Drive Buy Rating
- Royalty Pharma initiated with a Buy at Goldman Sachs
- Royalty Pharma appoints Ted Love as lead independent director
- These 3 “Strong Buy” Value Stocks Have over 30% Upside, According to Analysts – 9/17/2025
- Royalty Pharma Completes $2 Billion Senior Notes Offering